MANAGEMENT OF ENDOCRINE DISEASE disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Concurrent type 1 diabetes (T1D) and Addison’s disease (AD) is a rare combination of diseases and, in approximately one third of these patients, it is also combined with an autoimmune thyroid disease. Recently, it was shown that patients with both T1D and AD have a higher risk of premature death compared to patients with T1D alone, the most common causes of death being due to diabetic complications and cardiovascular disease. These patients receiving replacement therapies with both insulin and glucocorticoids face an increased risk of hypo- and hyperglycemia and diabetic ketoacidosis and have a higher risk of adrenal crisis than patients with AD alone. Treatment challenges include the opposing effects of insulin and glucocorticoids on glucose homeostasis and the need to balance and synchronize these two treatments. The rarity of this disease combination may explain the paucity of data on outcome and specific treatment strategies in this patient group. Based on this review, we suggest management strategies for their insulin and glucocorticoid replacement therapies and indicate future areas of research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is also a significantly different pattern of insulin requirements in patients with primary adrenal insufficiency and T1DM compared with patients with T1DM alone. While the percentage of daily coverage with basal insulin was lower in patients with adrenal insufficiency, the insulin requirement for prandial glycemic coverage was higher in patients with APS2 [12].”
From Onset of Addison Disease in a Patient Using the Advanced Hybrid Closed-Loop MiniMed 780G: Diagnostic Challenges (2025) · cites this paper as [12]
In the citing paper
“Co-incident type 1 diabetes is found in around 10% of patients with PAI (24, 25, 26).”
From ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency (2020) · cites this paper as [26]
Citations
Cites
Adverse metabolic and cardiovascular consequences of circadian misalignment
Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S., & Shea, S. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808180106 · Cited by 2,351
Cryptochromes mediate rhythmic repression of the glucocorticoid receptor
Lamia, K. A., Papp, S. J., Yu, R. T., Barish, G. D., Uhlenhaut, N. H., Jonker, J. W., Downes, M., & Evans, R. M. (2011) · Nature · doi:10.1038/nature10700 · Cited by 590
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Van Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
Erichsen, M. M., Løvås, K., Skinningsrud, B., Wolff, A. B., Undlien, D. E., Svartberg, J., Fougner, K. J., Berg, T. J., Bollerslev, J., Mella, B., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1368 · Cited by 422
21-hydroxylase, a major autoantigen in idiopathic Addison's disease
Winqvist, O., Karlsson, F. A., & Kämpe, O. (1992) · The Lancet · doi:10.1016/0140-6736(92)91829-w · Cited by 410
Secrest, A. M., Becker, D. J., Kelsey, S. F., LaPorte, R. E., & Orchard, T. J. (2010) · Diabetes · doi:10.2337/db10-0862 · Cited by 358
Epidemiological evidence for the links between sleep, circadian rhythms and metabolism
Gangwisch, J. E. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00663.x · Cited by 262
Diurnal cortisol decline is related to coronary calcification: CARDIA study
Matthews, K., Schwartz, J., Cohen, S., & Seeman, T. (2006) · Psychosomatic Medicine · doi:10.1097/01.psy.0000244071.42939.0e · Cited by 240
Kerrigan, J. R., Veldhuis, J. D., Leyo, S. A., Iranmanesh, A., & Rogol, A. D. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501158 · Cited by 228
Plat, L., Leproult, R., L’Hermite-Baleriaux, M., Fery, F., Mockel, J., Polonsky, K. S., & Van Cauter, E. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5978 · Cited by 225
High prevalence and increasing incidence of Addison's disease in western Norway
Løvås, K., & Husebye, E. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.t01-1-01552.x · Cited by 222
Eight-six Cases of Adison's Disease
Dunlop, D. (1963) · BMJ · doi:10.1136/bmj.2.5362.887 · Cited by 217
Isidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Hughes, J. W., Riddlesworth, T. D., DiMeglio, L. A., Miller, K. M., Rickels, M. R., McGill, J. B., & for the T1D Exchange Clinic Network (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2478 · Cited by 173
Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis
Nederstigt, C., Uitbeijerse, B. S., Janssen, L. G. M., Corssmit, E. P. M., de Koning, E. J. P., & Dekkers, O. M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0515 · Cited by 161
Continuous subcutaneous hydrocortisone infusion in Addison’s disease
Løvås, K., & Husebye, E. S. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0052 · Cited by 155
Quinkler, M., Miodini Nilsen, R., Zopf, K., Ventz, M., & Øksnes, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1114 · Cited by 126
Effect of Dehydroepiandrosterone Replacement on Insulin Sensitivity and Lipids in Hypoadrenal Women
Dhatariya, K., Bigelow, M. L., & Nair, K. S. (2005) · Diabetes · doi:10.2337/diabetes.54.3.765 · Cited by 114
Giordano, R., Guaraldi, F., Marinazzo, E., Fumarola, F., Rampino, A., Berardelli, R., Karamouzis, I., Lucchiari, M., Manetta, T., Mengozzi, G., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0681-z · Cited by 105
Autoimmune Polyendocrine Syndromes: Clues to Type 1 Diabetes Pathogenesis
Husebye, E. S., & Anderson, M. S. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.016 · Cited by 83
Dalin, F., Nordling Eriksson, G., Dahlqvist, P., Hallgren, Å., Wahlberg, J., Ekwall, O., Söderberg, S., Rönnelid, J., Olcén, P., Winqvist, O., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2522 · Cited by 82
Self-citationNeurogenetic basis for circadian regulation of metabolism by the hypothalamus
Cedernaes, J., Waldeck, N., & Bass, J. (2019) · Genes & Development · doi:10.1101/gad.328633.119 · Cited by 82
Cryer, P. (1997) · Hormone and Metabolic Research · doi:10.1055/s-2007-978997 · Cited by 78
Smans, L. C. C. J., Souverein, P. C., Leufkens, H. G. M., Hoepelman, A. I. M., & Zelissen, P. M. J. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0879 · Cited by 70
Meyer, G., Badenhoop, K., & Linder, R. (2016) · Clinical Endocrinology · doi:10.1111/cen.13043 · Cited by 63
Addison, T. (2008) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 58
Clues for early detection of autoimmune Addison's disease – myths and realities
Sævik, Å. B., Åkerman, A. ‐., Grønning, K., Nermoen, I., Valland, S. F., Finnes, T. E., Isaksson, M., Dahlqvist, P., Bergthorsdottir, R., Ekwall, O., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12699 · Cited by 55
Björnsdottir, S., Øksnes, M., Isaksson, M., Methlie, P., Nilsen, R. M., Hustad, S., Kämpe, O., Hulting, A., Husebye, E. S., Løvås, K., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12670 · Cited by 43
Naletto, L., Frigo, A. C., Ceccato, F., Sabbadin, C., Scarpa, R., Presotto, F., Costa, M. D., Faggian, D., Plebani, M., Censi, S., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0313 · Cited by 43
Triolo, T. M., Baschal, E. E., Armstrong, T. K., Toews, C. S., Fain, P. R., Rewers, M. J., Yu, L., Miao, D., Eisenbarth, G. S., Gottlieb, P. A., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1308 · Cited by 37
Elbelt, U., Hahner, S., & Allolio, B. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-1003 · Cited by 37
Christy, N. P., Holub, D. A., & Tomasi, T. B. (1962) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-22-2-155 · Cited by 35
Chantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Bergthorsdottir, R., Gudbjörnsdottir, S., Svensson, A.-M., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0657 · Cited by 30
Self-citationJohannsson, G., Lennernäs, H., Marelli, C., Rockich, K. T., & Skrtic, S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1212 · Cited by 29
Self-citationGuarnotta, V., Ciresi, A., Pillitteri, G., & Giordano, C. (2018) · Clinical Endocrinology · doi:10.1111/cen.13554 · Cited by 29
Likhari, T., Magzoub, S., Griffiths, M. J., Buch, H., & Gama, R. M. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2007.058321 · Cited by 28
Chantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Svensson, A., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0751 · Cited by 24
Self-citationStarke, A. A. R., Valverde, I., Bottazzo, G. F., Tsotsalas, M., & Zimmermann, H. (1983) · Diabetologia · doi:10.1007/bf00253197 · Cited by 11
Chantzichristos, D., Persson, A., Miftaraj, M., Eliasson, B., Svensson, A.-M., & Johannsson, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02064 · Cited by 9
Self-citationInsufficient evidence to favour prednisolone over hydrocortisone in glucocorticoid replacement
Pearce, S. H. S. (2014) · BMJ · doi:10.1136/bmj.g5510 · Cited by 4
Cited by
Popoviciu, M. S., Kaka, N., Sethi, Y., Patel, N., Chopra, H., & Cavalu, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030422 · Cited by 185
“The incorrect association of the two therapies predisposes patients to the risk of hypo- or hyperglycemia, diabetic ketoacidosis or Addisonian crisis [29].”
BackgroundENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0361 · Cited by 107
Fröhlich‐Reiterer, E., Elbarbary, N. S., Simmons, K., Buckingham, B., Humayun, K. N., Johannsen, J., Holl, R. W., Betz, S., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13445 · Cited by 74
“education, emergency cards, and adjustment of glucocorticoid treatment (stress dose glucocorticoids) in case of intercurrent medical illness, trauma, surgery, or invasive procedures, as well as to identify and treat adrenal crises in a timely manner.(124)”
BackgroundClinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient’s Perspective
Claessen, K. M. J. A., Andela, C. D., Biermasz, N. R., & Pereira, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701365 · Cited by 33
Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review
Caetano, C. M., & Malchoff, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.897211 · Cited by 29
Metadata
- Authors
- Chantzichristos, D., Eliasson, B., & Johannsson, G.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07
- Volume
- 183
- Issue
- 1
- Pages
- R1-R11
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W3017293870
- Cited by
- 21
- References
- 41
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 2
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF17OC0026978)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- Addison's disease, type 1 diabetes, adrenal insufficiency, glucocorticoid replacement therapy, insulin therapy, adrenal crisis, diabetic ketoacidosis, hypoglycemia, hyperglycemia, glucose homeostasis, autoimmune thyroid disease, disease burden, premature mortality
- MeSH terms
- Addison Disease, Diabetes Mellitus, Type 1, Glucocorticoids, Humans, Insulin, Survival Analysis, Treatment Outcome, Cost of Illness, Disease Management, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.